PROCEDURAL STEPS TAKEN AFTER GRANTING THE MARKETING 
AUTHORISATION 
For procedures finalised after 1 April 2004 please refer to module 8B.  
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On 2 April 1998, the European Commission approved a variation (Type I following type II) for 
the serum-free production of Epoetin beta.  
On 2 April 1998, the European Commission approved an Annex II application (Extension of the 
Marketing  Authorisation)  for  7  additional  strengths/pharmaceutical  forms  (solution  for 
injection).  The  relevant  amendments  have  been  incorporated  in  the  relevant  sections  of  the 
Commission Decision and of this EPAR. 
On  1  October  1998,  the  European  Commission  approved  a  type  I  variation  submitted  by  the 
company  relating  to  the  change  of  name  of  the  solution  for  injection  presentations  to 
“NeoRecormon  <strength>  IU  solution  for  injection  in  pre-filled  syringe”.  The  relevant 
amendments have been incorporated in the relevant sections of the Commission Decision and of 
this EPAR. 
On 11 November 1998, the European Commission approved a type II variation for the extension 
of the shelf life to 3 years at 2 – 8 °C for NeoRecormon (powder and solvent for solution for 
injection) for the following strengths: 500 IU, 1000 IU, 2000 IU, 5000 IU and 10000 IU single 
dose and 50000 IU and 10000 IU multidose. The relevant amendments have been incorporated 
in the relevant sections of the Commission Decision and of this EPAR. 
On  11 November  1998,  the  European  Commission  approved  a type II variation to  change the 
needle size for NeoRecormon in pre-filled syringe and to update the SPC, PL and labels for all 
presentations. The relevant amendments have been incorporated in the relevant sections of the 
Commission Decision and of this EPAR. 
On  2  July  1998,  the  European  Commission  notified  the  EMEA,  the  Marketing  Authorisation 
Holder and the members of the Standing Committee of a type I variation (change in bulk buffer) 
which does not require any amendment to the Commission Decision.  
On  7 May 1999 (date  of  notification:  12 March  1999), the European  Commission  approved  a 
transfer  of  Marketing  Authorisation  from  Boehringer  Mannheim  GmbH  (Germany)  to  Roche 
Registration  Ltd.  (United  Kingdom).  The  relevant  amendments  have  been  incorporated  in  the 
relevant sections of the Commission Decision and of this EPAR. 
On  1  July  1999,  the  European  Commission  approved  a  type  I  variation:  changes  following 
modification  of  the  manufacturing  authorisation  (transfer  of  Marketing  Authorisation).  The 
relevant  amendments  have  been  incorporated  in  the  relevant  sections  of  the  Commission 
Decision and of this EPAR. 
On  16  July  1999,  the  European  Commission  approved  a  type  II  variation:  additional 
manufacturing  site  for  the  NeoRecormon  pre-filled  syringes  500  IU-20000  IU  (Roche 
Diagnostics  GmbH,  Mannheim).  The  relevant  amendments  have  been  incorporated  in  the 
relevant sections of this EPAR. 
On 10 February 2000, the European Commission approved a type II variation: changes to SPC, 
labelling  and  package  leaflet  with  regards  to  new  template,  amendments  to  sections  4.8  as  
a result of second PSUR and update of the addresses of local representatives in package leaflet. 
The  relevant  amendments  have  been  incorporated  in  the  relevant  sections  of  the  Commission 
Decision and of this EPAR. 
On  10  February  2000,  the  European  Commission  approved  three  Annex  II  application 
(Extension  of  the  Marketing  Authorisation)  for  2  additional  strengths  of  the  solution  for 
injection in pre-filled syringes and 1 additional strength of the powder and solvent for solution 
for  injection  in  cartridge.  The  relevant  amendments  have  been  incorporated  in  the  relevant 
sections of the Commission Decision and of this EPAR. 
1/2 
   EMEA 2004 
 
 
 
 
 
• 
On  20  March  2001,  the  European  Commission  approved  a  type  II  variation:  additional 
indication.  The  relevant  amendments  have  been  incorporated  in  the  relevant  sections  of  the 
Commission Decision and of this EPAR.   
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Change to summary of product characteristics (section 4.2) and 
package leaflet to update the posology section in order to include a 
new, once weekly, frequency of administration. 
Change in the batch size of finished product 
Change in test methods for the active substance 
Change in test procedures of the medicinal product 
Change in specifications for the active substance 
Minor change in labelling and package leaflet not connected with the 
SPC (Art. 61(3) Notification) 
Minor change in manufacturing of the medicinal product 
Renewal 
Change to summary of product characteristics (section 4.2) and 
package leaflet to update the posology section in order to include a 
new, once weekly, frequency of administration. 
Additional secondary packing site 
Update of Summary of Product Characteristics and Package Leaflet 
Additional secondary packing site 
Additional secondary packing site 
Change in the batch size of finished product 
Change(s) to the manufacturing process for the active substance 
Addition of new strength 
II/15 
I/16 
II/17 
I/II/18 
II/19 
N/20 
I/21 
R/22 
II/23 
I/24 
II/26 
I/27 
I/28 
I/29 
II/30 
X/31 
II 
I 
II 
I/II 
II 
N 
I 
R 
II 
I 
II 
I 
I 
I 
II 
X 
Notification/ 
Opinion 
issued on2 
31.05.01 
Commission 
Decision 
Issued/amen
ded on 
17.09.01 
14.05.01 
27.06.01 
27.06.01 
15.11.01 
21.02.02 
28.05.02 
21.08.02 
25.10.02 
18.12.02 
25.10.02 
08.11.02 
23.01.03 
25.04.03 
25.09.03 
04.07.01 
06.07.01 
19.11.01 
29.09.01 
01.03.02 
22.08.02 
03.12.02 
05.11.02 
17.03.03 
05.11.02 
08.11.02 
27.01.03 
30.04.03 
23.02.04 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
                                                                                                     2/2                                                                         EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
 
